26
|
Barry AR, Lee C. Pharmacist- or Nurse Practitioner–Led Assessment and Titration of Sacubitril/Valsartan in a Heart Failure Clinic: A Cohort Study. Can J Hosp Pharm 2020. [DOI: 10.4212/cjhp.v73i3.2996] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
ABSTRACTBackground: Sacubitril/valsartan is a first-in-class angiotensin receptor–neprilysin inhibitor indicated in the management of heart failure with reduced ejection fraction, based on the results of the PARADIGM-HF trial. Practice-based studies are needed to validate its effect in real-world settings. Clinical pharmacists are ideally situated to assess and titrate sacubitril/valsartan.Objective: To evaluate the utilization, safety, and tolerability of sacubitril/ valsartan in a multidisciplinary heart failure clinic, with assessment and titration by a clinical pharmacist or a nurse practitioner.Methods: A retrospective cohort study was conducted at a heart failure clinic in Abbotsford, Canada. Included were adult patients with heart failure who were currently or formerly taking sacubitril/valsartan. Data collected for the period October 2015 to February 2019 included patient characteristics, New York Heart Association (NYHA) classification, concurrent medications, sacubitril/valsartan dose, adverse effects, and discontinuation rate.Results: In total, 128 patients were included. Mean age was 70.1 years, 98 (77%) of the patients were men, and 79 (62%) had NYHA class 2 heart failure. The clinical pharmacist managed care for 78 (61%) of the patients, and the nurse practitioner managed care for 50 (39%). Forty-one (32%) of the patients met modified PARADIGM-HF inclusion criteria. Eighty-five (66%) of the patients achieved the target dose of sacubitril/valsartan, with similar proportions for the clinical pharmacist and nurse practitioner groups, over a mean of 2.2 clinic visits. Patients who achieved the sacubitril/valsartan target dose, relative to those who did not, were significantly younger and had higher mean systolic blood pressure at baseline. Twenty-nine percent of patients (35/119) had an improvement in NYHA classification from before initiation of sacubitril/valsartan to achievement of target or maximally tolerated dose. Eighty-five (66%) of the patients experienced an adverse effect, primarily hypotension, and 12 (9%) required a dose reduction. Only 9 (7%) patients discontinued therapy.Conclusions: This study demonstrates the real-world safety and tolerability of sacubitril/valsartan in the treatment of heart failure, and reinforces that clinical pharmacists can effectively assess and titrate medications in a multidisciplinary heart failure clinic.RÉSUMÉContexte : Le sacubitril-valsartan est un inhibiteur novateur des récepteurs de l’angiotensine-néprilysine, indiqué dans la gestion de l’insuffisance cardiaque accompagnée d’une baisse de la fraction d’éjection, selon les résultats de l’essai PARADIGM-HF. Des études fondées sur la pratique sont nécessaires pour valider ses effets en contexte réel. Les pharmaciens cliniciens sont bien placés pour évaluer et titrer le sacubitril-valsartan.Objectif : Évaluer l’utilisation, l’innocuité et le seuil de tolérance du sacubitril-valsartan en clinique multidisciplinaire d’insuffisance cardiaque, l’évaluation et le titrage étant effectués par un pharmacien clinicien ou une infirmière praticienne.Méthodes : Une étude de cohorte rétrospective a été menée au sein d’une clinique d’insuffisance cardiaque à Abbotsford, au Canada. Les patients adultes inclus dans l’étude souffraient d’insuffisance cardiaque, ils prenaient ou avaient pris du sacubitril-valsartan. Les données recueillies entre octobre 2015 et février 2019 comprenaient les caractéristiques des patients, la classification de la New York Heart Association (NYHA), les médicaments pris de façon concomitante, la dose de sacubitril-valsartan, les effets secondaires et le taux d’abandon.Résultats : Au total, 128 patients ont participé à l’étude. L’âge moyen des patients était de 70,1 ans, 98 d’entre eux (77 %) étaient des hommes et 79 (62 %) souffraient d’une insuffisance cardiaque de classe 2 selon la classification de la NYHA. Le pharmacien clinicien gérait les soins de 78 patients (61 %) et la pharmacienne praticienne gérait ceux de 50 patients (39 %). Quarante-et-un patients (32 %) répondaient aux critères d’inclusion modifiés de PARADIGM-HF. Quatre-vingt-cinq (66 %) patients atteignaient le dosage ciblé de sacubitril-valsartan dans des proportions similaires entre le groupe du pharmacien clinicien et celui de l’infirmière praticienne, à raison d’une moyenne de 2,2 visites en clinique. Les patients ayant atteint le dosage ciblé de sacubitril-valsartan, par rapport à ceux ne l’ayant pas atteint, étaient considérablement plus jeunes et leur tension artérielle systolique moyenne de base était plus élevée. Une amélioration de la classification NYHA a été observée chez 29 % des patients (35/119) entre le début de la prise de sacubitril-valsartan et l’atteinte du dosage ciblé ou de la dose maximale tolérée. Des effets secondaires ont été observés chez 85 patients (66 %), principalement une hypotension, et 12 d’entre eux (9 %) ont dû réduire la dose. Seuls 9 patients (7 %) ont dû abandonner la thérapie.Conclusions : Cette étude démontre l’innocuité et le seuil de tolerance en contexte réel du sacubitril-valsartan pour le traitement de l’insuffisance cardiaque. Elle renforce le fait que les pharmaciens cliniciens peuvent efficacement évaluer et titrer des médicaments au sein d’une Clinique d’insuffisance cardiaque multidisciplinaire.
Collapse
|
27
|
Webb CA, Barry AR. Colchicine for Secondary Cardiovascular Prevention: A Systematic Review. Pharmacotherapy 2020; 40:575-583. [PMID: 32259308 DOI: 10.1002/phar.2401] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Despite advancements in medical and interventional therapy, patients with cardiovascular disease (CVD) continue to have residual risk for recurrent cardiovascular events. Colchicine has a unique antiinflammatory mechanism that has generated interest in its potential use as a secondary cardiovascular preventive therapy. The objective of this systematic review was to evaluate the evidence for long-term (6 months or more) colchicine therapy in patients with established CVD. A search of Medline and Embase from inception to February 2020 was performed. Included were randomized controlled trials (RCTs) or propensity score-matched observational studies that compared colchicine (at any dose) with placebo or no treatment. Outcomes of interest included any major adverse cardiovascular event, cardiovascular hospitalization, coronary artery restenosis, cardiovascular death, or all-cause death. Five RCTs were included. The dose of colchicine ranged from 0.5 mg/day to 0.6 mg twice/day, and follow-up ranged from ~6-36 months. Two trials (one double blind and one single blind) showed a reduction in composite outcomes of major adverse cardiovascular events. One study failed to demonstrate a benefit with colchicine in restenosis or recurrent ischemia after angioplasty; however, it was conducted before the routine use of modern percutaneous coronary intervention and medical therapies. In contrast, a more recent trial found that colchicine reduced the rate of in-stent restenosis in patients who received a bare metal stent. Finally, one trial in patients with heart failure with reduced ejection fraction did not observe a benefit in death or heart failure hospitalization with colchicine despite a reduction in inflammatory markers. No trial demonstrated a reduction in cardiovascular or all-cause death, and most trials showed an increase in the rate of diarrhea with colchicine. Overall, colchicine has demonstrated promising results for the secondary prevention of CVD; however, further studies are required to confirm these findings before colchicine can be routinely recommended in practice.
Collapse
|
28
|
Barry AR, Lee C. Pharmacist- or Nurse Practitioner-Led Assessment and Titration of Sacubitril/Valsartan in a Heart Failure Clinic: A Cohort Study. Can J Hosp Pharm 2020; 73:186-192. [PMID: 32616944 PMCID: PMC7308157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
BACKGROUND Sacubitril/valsartan is a first-in-class angiotensin receptor-neprilysin inhibitor indicated in the management of heart failure with reduced ejection fraction, based on the results of the PARADIGM-HF trial. Practice-based studies are needed to validate its effect in real-world settings. Clinical pharmacists are ideally situated to assess and titrate sacubitril/valsartan. OBJECTIVE To evaluate the utilization, safety, and tolerability of sacubitril/valsartan in a multidisciplinary heart failure clinic, with assessment and titration by a clinical pharmacist or a nurse practitioner. METHODS A retrospective cohort study was conducted at a heart failure clinic in Abbotsford, Canada. Included were adult patients with heart failure who were currently or formerly taking sacubitril/valsartan. Data collected for the period October 2015 to February 2019 included patient characteristics, New York Heart Association (NYHA) classification, concurrent medications, sacubitril/valsartan dose, adverse effects, and discontinuation rate. RESULTS In total, 128 patients were included. Mean age was 70.1 years, 98 (77%) of the patients were men, and 79 (62%) had NYHA class 2 heart failure. The clinical pharmacist managed care for 78 (61%) of the patients, and the nurse practitioner managed care for 50 (39%). Forty-one (32%) of the patients met modified PARADIGM-HF inclusion criteria. Eighty-five (66%) of the patients achieved the target dose of sacubitril/valsartan, with similar proportions for the clinical pharmacist and nurse practitioner groups, over a mean of 2.2 clinic visits. Patients who achieved the sacubitril/valsartan target dose, relative to those who did not, were significantly younger and had higher mean systolic blood pressure at baseline. Twenty-nine percent of patients (35/119) had an improvement in NYHA classification from before initiation of sacubitril/valsartan to achievement of target or maximally tolerated dose. Eighty-five (66%) of the patients experienced an adverse effect, primarily hypotension, and 12 (9%) required a dose reduction. Only 9 (7%) patients discontinued therapy. CONCLUSIONS This study demonstrates the real-world safety and tolerability of sacubitril/valsartan in the treatment of heart failure, and reinforces that clinical pharmacists can effectively assess and titrate medications in a multidisciplinary heart failure clinic.
Collapse
|
29
|
Barry AR. Severe Hypoglycemia in a Patient With Type 1 Diabetes Mellitus Recently Started on Sacubitril/Valsartan: A Case Report. CJC Open 2020; 2:176-178. [PMID: 32462132 PMCID: PMC7242494 DOI: 10.1016/j.cjco.2020.02.002] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2020] [Accepted: 02/06/2020] [Indexed: 12/11/2022] Open
Abstract
This report describes an episode of severe hypoglycemia in a 55-year-old woman with type 1 diabetes mellitus approximately 2 weeks after initiating sacubitril/valsartan for heart failure. She was receiving a continuous subcutaneous insulin infusion and denied any severe hypoglycemic events in the prior 13 years. She experienced a second hypoglycemic episode 1 week later. She subsequently reduced her insulin dose and continued on sacubitril/valsartan. Eight months later, she did not have any recurrent hypoglycemic episodes. Clinicians should be aware of this potential adverse effect and educate patients on concomitant insulin therapy to monitor for symptoms of hypoglycemia when initiating sacubitril/valsartan.
Collapse
|
30
|
Barry AR, Semchuk WM, Thompson A, LeBras MH, Koshman SL. Use of low-dose acetylsalicylic acid for cardiovascular disease prevention: A practical, stepwise approach for pharmacists. Can Pharm J (Ott) 2020; 153:153-160. [PMID: 32528599 DOI: 10.1177/1715163520909137] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Low-dose acetylsalicylic acid (ASA) is recommended in patients with established cardiovascular disease. However, the role of ASA in those without cardiovascular disease (i.e., primary prevention) is less clear, which has led to discordance among Canadian guidelines. In 2018, 3 double-blind, randomized controlled trials were published that evaluated ASA 100 mg daily versus placebo in patients without established cardiovascular disease. In the ASPREE trial, ASA did not reduce the risk of all-cause death, dementia, or persistent physical disability in patients ≥70 years of age but increased the risk of major bleeding. In the ARRIVE trial, ASA failed to lower the risk of a composite of cardiovascular events but increased any gastrointestinal bleeding in patients at intermediate risk of cardiovascular disease. In the ASCEND trial, ASA significantly reduced the primary composite cardiovascular outcome in patients with diabetes for a number needed to treat of 91 over approximately 7.4 years. Yet major bleeding was increased with ASA for a number needed to harm of 112. Therefore, in most situations, ASA should not be recommended for primary cardiovascular prevention. However, there are additional indications for ASA beyond cardiovascular disease. Thus, a sequential algorithm was developed based on contemporary evidence to help pharmacists determine the suitability of ASA in their patients and play an active role in educating their patients about the potential benefits (or lack thereof) and risks of ASA. Can Pharm J (Ott) 2020;153:xx-xx.
Collapse
|
31
|
Barry AR, Chris CE. Treatment of chronic noncancer pain in patients on opioid therapy in primary care: A retrospective cohort study. Can Pharm J (Ott) 2020; 153:52-58. [PMID: 32002103 DOI: 10.1177/1715163519887766] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Background This study sought to characterize the real-world treatment of chronic noncancer pain (CNCP) in patients on opioid therapy in primary care. Methods A retrospective cohort study from 2014-18 was conducted at a multidisciplinary primary care clinic in Chilliwack, British Columbia. Included were adults on daily opioid therapy for CNCP. Patients receiving palliative care or ≤1 visit were excluded. Outcomes of interest included use of opioid/nonopioid pharmacotherapy, number/frequency of visits and proportion of patients able to reduce/discontinue opioid therapy. Results Seventy patients (mean age 53 years, 53% male, 51% back pain) were included. Median follow-up was 6 visits over 12 months. Sixty-two patients (89%) reduced their opioid dose, 6 patients had no change and 2 patients required a dose increase. Mean opioid dose was reduced from 183 to 70 mg morphine equivalents daily. Twenty-four patients (34%) discontinued opioid therapy, 6 patients (9%) transitioned to opioid agonist therapy and 6 patients (9%) breached their opioid treatment agreement. Nonopioid pharmacotherapy included nonsteroidal anti-inflammatory drugs (64%), gabapentinoids (63%), tricyclic antidepressants (56%) and nabilone (51%). Discussion Over half of patients were no longer on opioid therapy by the end of the study. Most patients had a disorder (e.g., back pain) for which opioids are generally not recommended. Overall mean opioid dose was reduced from baseline by approximately 60% over 1 year. Lack of access to specialized pain treatments may have accounted for high nonopioid pharmacotherapy usage. Conclusions This study demonstrates that treatment of CNCP and opioid tapering can successfully be achieved in a primary care setting. Can Pharm J (Ott) 2020;153:xx-xx.
Collapse
|
32
|
Barry AR, Babadagli HE, Chen JW, May TA, McMillan CL, Omar MA, Pollmann DM, Zhou JS, Ackman ML. Review of the top 5 cardiology studies of 2017-18. Can Pharm J (Ott) 2020; 153:32-36. [PMID: 32002100 PMCID: PMC6966269 DOI: 10.1177/1715163519882464] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2023]
|
33
|
Barry AR, Wang EH, Chua D, Pearson GJ. Comparison of Preventive Cardiovascular Pharmacotherapy in Surgical vs Percutaneous Coronary Revascularization. CJC Open 2019; 1:297-304. [PMID: 32159124 PMCID: PMC7063635 DOI: 10.1016/j.cjco.2019.09.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2019] [Accepted: 09/10/2019] [Indexed: 11/27/2022] Open
Abstract
Background Data suggest that patients who undergo coronary artery bypass grafting (CABG) have a lower rate of secondary preventive cardiovascular pharmacotherapy use compared with patients who undergo percutaneous coronary intervention (PCI). This study sought to assess the rate of use of preventive pharmacotherapy at discharge in patients who underwent CABG vs PCI post–acute coronary syndrome (ACS). Methods A prospective cohort study was conducted at St Paul’s Hospital in Vancouver, Canada. Patients aged ≥ 18 years who presented with an ACS and underwent CABG or PCI between January and November 2018 were included. Data on preventive pharmacotherapy use and reasons for justified nonuse (eg, intolerance, contraindication) were collected. Results A total of 275 patients were included. Mean age was 65 years, and 83% were male. Overall, 141 patients (51%) underwent CABG and 134 patients (49%) underwent PCI. All patients received acetylsalicylic acid, but more patients who underwent CABG received 325 mg (vs 80-81 mg) compared to PCI (25% vs 1%, P < 0.01). Use of P2Y12 inhibitors was higher in patients who underwent PCI (primarily ticagrelor) compared with patients who underwent CABG (primarily clopidogrel) (99% vs 26%, P < 0.01). All patients who underwent CABG received a β-blocker vs 96% of patients who underwent PCI (P = 0.017). Use of angiotensin-modulating agents was higher in patients who underwent PCI (98% vs 65%, P < 0.01). Statin use was similar between groups (99% vs 99%, P = 0.96), but more patients who underwent PCI received maximum-dose therapy (89% vs 64%, P < 0.01). Conclusions Use of acetylsalicylic acid, β-blockers, and statins in patients post-ACS was high regardless of revascularization strategy, whereas P2Y12 inhibitors and angiotensin-modulating agents were underused in patients who underwent CABG even after adjusting for justified nonuse.
Collapse
|
34
|
Barry AR, Turgeon RD. Newer Oral Antihyperglycemics: From Seinfeld to Breaking Bad. Can J Hosp Pharm 2019. [DOI: 10.4212/cjhp.v72i5.2932] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
35
|
Barry AR, Turgeon RD. Newer Oral Antihyperglycemics: From Seinfeld to Breaking Bad. Can J Hosp Pharm 2019; 72:385-387. [PMID: 31692662 PMCID: PMC6799970] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
|
36
|
Prasad M, Loewen PS, Shalansky S, Salmasi S, Barry AR. Health Authority Pharmacists’ Perceptions of Independent Pharmacist Prescribing. Can J Hosp Pharm 2019. [DOI: 10.4212/cjhp.v72i3.2898] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
ABSTRACTBackground: In many jurisdictions, the pharmacist’s role continues to evolve from drug distribution–based service delivery to expanded scopes of practice, including independent prescribing of medications. Objectives: To assess health authority–based pharmacists’ attitudes, be-liefs, and perceptions about independent prescribing, to determine how independent prescribing may affect their behaviour, and to identify perceived barriers and enablers to incorporating it into their practice.Methods: An anonymous, cross-sectional online survey of 677 health authority–based pharmacists employed by Lower Mainland Pharmacy Services in British Columbia collected information in the following domains: demographic characteristics; attitudes, beliefs, and perceptions regarding pharmacist prescribing; anticipated effect of pharmacist prescribing on behaviour; likelihood of applying for this authority, if granted; and barriers and enablers to applying for prescribing authority and incorporating prescribing into their practice. A multivariate regression analysis was performed.Results: A total of 266 pharmacists (39.3%) responded to the survey. Most respondents agreed that prescribing is important to the profession and relevant to their practice, and that it might enhance job satisfaction. Additionally, respondents agreed that they had the expertise to prescribe. Respondents perceived prescribing as having the potential to positively affect behaviour, including deprescribing, prescribing at time of discharge or transfer, and renewing medications. Enablers to applying for pharma-cist prescribing authority included perceived positive impact on patient care and the profession, level of support from management and coworkers, and personal ability. No barriers were identified. About two-thirds of phar-macists indicated they would likely apply for prescribing authority if it were granted through legislation. Pharmacists with a clinical practice or research role were significantly more likely to apply to be a prescriber, whereas those with more than 10 years of experience were less likely to apply.Conclusions: In this study, health authority–based pharmacists held positive attitudes and beliefs about the value and impact of independent prescribing of medications on their practice and the profession. There were no perceived barriers to applying for prescribing authority or to incorporating prescribing into practice.RÉSUMÉContexte : Dans bien des provinces, le rôle du pharmacien ne cesse d’évoluer, depuis la prestation de services fondée sur la distribution de médicaments à des champs de pratique élargis, comprenant le droit de prescription autonome des médicaments. Objectifs : Évaluer les attitudes, les croyances et les opinions des pharmaciens rattachés à des régies de santé concernant le droit de prescription autonome, déterminer l’influence de ce droit sur leurs habitudes et recenser les éléments qui, selon eux, entravent ou facilitent l’intégration de ce droit dans leur pratique.Méthodes : Une enquête transversale anonyme en ligne s’adressant à 677 pharmaciens rattachés à une régie de santé et employés par les services de pharmacie des basses-terres continentales en Colombie-Britannique a permis de recueillir de l’information sur les domaines suivants : caractéris-tiques démographiques; attitudes, croyances et opinions concernant le droit de prescrire des pharmaciens; effets envisagés sur les habitudes du droit de prescrire accordé aux pharmaciens; probabilité de demander ce droit, s’il existe; et les éléments entravant ou facilitant la demande du droit de prescrire et l’intégration de ce droit dans leur pratique. Une analyse de régression multivariée a été réalisée.Résultats : Au total, 266 pharmaciens (39,3 %) ont répondu au sondage. La plupart d’entre eux ont affirmé que le droit de prescrire est important pour la profession et pertinent dans le cadre de leur pratique et que cet acte pourrait accroître leur satisfaction au travail. De plus, les répondants affirmaient qu’ils possédaient l’expertise requise pour prescrire. Selon eux, le droit de prescrire pouvait influencer positivement leurs habitudes, notamment en ce qui concerne l’interruption de la prescription, la prescription au moment du congé ou d’un transfert et le renouvellement de médicaments. Parmi les éléments incitant les pharmaciens à solliciter le droit de prescrire, on comptait les effets positifs présumés sur les soins offerts aux patients et sur la profession, le soutien de la part de la direction et des collègues et les capacités personnelles. Aucun obstacle n’a été recensé. Environ deux tiers des pharmaciens ont indiqué qu’ils solliciteraient probablement le droit de prescrire s’il était accordé par la loi. Les pharmaciens en pratique clinique et ceux en recherche étaient beaucoup plus enclins à faire la demande pour devenir prescripteurs alors que ceux comptabilisant plus de dix ans d’expérience étaient moins enclins à faire la demande.Conclusions : Dans la présente étude, les pharmaciens rattachés à une régie de santé affichaient une attitude et des croyances positives à propos de la valeur du droit de prescription autonome des médicaments et des effets qu’il aurait sur leur pratique et la profession. On n’a recensé aucun élément perçu comme un obstacle à la formulation d’une demande du droit de prescrire ou à l’inclusion de ce rôle dans la pratique.
Collapse
|
37
|
Tan JT, Barry AR. Coenzyme Q10 supplementation in the management of statin-associated myalgia. Am J Health Syst Pharm 2019; 74:786-793. [PMID: 28546301 DOI: 10.2146/ajhp160714] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
|
38
|
Prasad M, Loewen PS, Shalansky S, Salmasi S, Barry AR. Health Authority Pharmacists' Perceptions of Independent Pharmacist Prescribing. Can J Hosp Pharm 2019; 72:185-193. [PMID: 31258163 PMCID: PMC6592659] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
BACKGROUND In many jurisdictions, the pharmacist's role continues to evolve from drug distribution-based service delivery to expanded scopes of practice, including independent prescribing of medications. OBJECTIVES To assess health authority-based pharmacists' attitudes, beliefs, and perceptions about independent prescribing, to determine how independent prescribing may affect their behaviour, and to identify perceived barriers and enablers to incorporating it into their practice. METHODS An anonymous, cross-sectional online survey of 677 health authority-based pharmacists employed by Lower Mainland Pharmacy Services in British Columbia collected information in the following domains: demographic characteristics; attitudes, beliefs, and perceptions regarding pharmacist prescribing; anticipated effect of pharmacist prescribing on behaviour; likelihood of applying for this authority, if granted; and barriers and enablers to applying for prescribing authority and incorporating prescribing into their practice. A multivariate regression analysis was performed. RESULTS A total of 266 pharmacists (39.3%) responded to the survey. Most respondents agreed that prescribing is important to the profession and relevant to their practice, and that it might enhance job satisfaction. Additionally, respondents agreed that they had the expertise to prescribe. Respondents perceived prescribing as having the potential to positively affect behaviour, including deprescribing, prescribing at time of discharge or transfer, and renewing medications. Enablers to applying for pharmacist prescribing authority included perceived positive impact on patient care and the profession, level of support from management and coworkers, and personal ability. No barriers were identified. About two-thirds of pharmacists indicated they would likely apply for prescribing authority if it were granted through legislation. Pharmacists with a clinical practice or research role were significantly more likely to apply to be a prescriber, whereas those with more than 10 years of experience were less likely to apply. CONCLUSIONS In this study, health authority-based pharmacists held positive attitudes and beliefs about the value and impact of independent prescribing of medications on their practice and the profession. There were no perceived barriers to applying for prescribing authority or to incorporating prescribing into practice.
Collapse
|
39
|
Barry AR, Egan G, Turgeon RD, Leung M. Evaluation of Physical Assessment Education for Practising Pharmacists: A Cross-Sectional Survey. Can J Hosp Pharm 2019. [DOI: 10.4212/cjhp.v72i1.2865] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
ABSTRACTBackground: Pharmacists are now seeking to incorporate physical assess-ment (PA) into their practices. This trend prompted the creation, by the British Columbia Branch of the Canadian Society of Hospital Pharma-cists, of a 30-h course specifically designed for practising pharmacists.Objective: To evaluate pharmacists’ knowledge, skills, and confidence in performing PA after completing the course.Methods: All course participants were invited to complete 2 anonymous online surveys, immediately and 6 months after course completion.Results: Of the 218 participants, 82 (38%) responded to the survey administered immediately after the course, and 77 (35%) completed this survey in full. About half of the respondents (39/79 [49%]) reported use of PA on a real patient before taking the course. Lack of formal training and lack of comfort were the most frequently selected barriers to performing PA. All respondents (79/79) agreed that the course had improved their knowledge of PA, 96% (76/79) agreed that it had improved their skills, and 90% (71/79) agreed that it had improved their ability to care for patients. In addition, 61% (48/79) and 67% (53/79), respectively, agreed that they felt confident performing PA and intervening with regard to a patient’s drug therapy on the basis of physical findings. Thirty-eight (17%) of the course participants completed the 6-month follow-up survey. In that survey, the most frequently selected barrier to performing PA was lack of time. Paired data, available for 23 respondents, showed a significant increase in use of PA on real patients over time (p = 0.013 by 2 test). However, there was no significant improvement in confidence in performing PA or intervening on a patient’s drug therapy on the basis of physical findings (p > 0.05 by 2-sided t test). The primary limitation of this study was potential responder bias.Conclusions: A PA course designed for pharmacists improved participants’ self-reported knowledge and skills, as well as self-perceived ability to care for patients. Six months after the course, two-thirds of respondents had used PA in practice. However, there was no improvement in confidence in performing such assessments or using the findings to intervene on a patient’s drug therapy.RÉSUMÉContexte : Les pharmaciens cherchent désormais à ajouter l’examen physique à leurs pratiques. Cette tendance a motivé la section britanno-colombienne de la Société canadienne des pharmaciens d’hôpitaux à créer un cours de 30 heures conçu spécialement pour les pharmaciens en exercice.Objectif : Évaluer les connaissances, les compétences et le degré d’aisance des pharmaciens ayant suivi le cours portant sur la réalisation d’examens physiques.Méthodes : Tous les participants au cours ont été invités à remplir deux sondages anonymes en ligne : l’un à la fin du cours et l’autre six mois après la fin du cours.Résultats : Des 218 participants, 82 (38 %) ont répondu partiellement au sondage mené immédiatement à la fin du cours et 77 (35 %) y ont répondu en entier. Environ la moitié des répondants (39/79 [49 %]) ont indiqué avoir réalisé un examen physique en situation réelle avant d’avoir suivi le cours. Les facteurs les plus fréquents propres à dissuader le pharma-cien de réaliser un examen physique étaient l’absence de formation officielle et le manque d’aisance. Tous les répondants ont indiqué que le cours avait accru leurs connaissances de l’examen physique, 96 % (76/79) ont affirmé qu’il avait amélioré leurs compétences et 90 % (71/79) ont déclaré qu’il avait amélioré leur capacité à soigner les patients. De plus, 61 % (48/79) et 67 % d’entre eux (53/79) ont indiqué respectivement qu’ils se sentaient à l’aise de réaliser des examens physiques et d’agir sur la pharmacothérapie du patient en fonction des résultats de l’examen. Trente-huit (17 %) participants ont répondu au sondage mené six mois après le cours. Ce sondage a révélé que le manque de temps était le facteur le plus souvent évoqué pour faire obstacle à la réalisation d’examens physiques. Des données appariées de 23 répondants ont montré une aug-mentation significative du recours à l’examen physique en situation réelle au fil du temps (p = 0,013 par test 2). Cependant, on n’a noté aucune amélioration significative de l’aisance à réaliser des examens physiques ou à agir sur la pharmacothérapie d’un patient en fonction des résultats d’un examen physique (p > 0,05 par un test t bilatéral). La principale limite de la présente étude était un biais potentiel dans les réponses. Conclusions : Un cours sur l’examen physique conçu pour les pharmaciens a amélioré les connaissances et les compétences autodéclarées des participants ainsi que ce qu’ils croient être leurs capacités à soigner les patients. Six mois après le cours, deux tiers des répondants avaient réalisé un examen physique dans leur pratique. Cependant, on n’a noté aucune amélioration de l’aisance à réaliser de tels examens ou à en utiliser les résultats pour agir sur la pharmacothérapie du patient.
Collapse
|
40
|
Salmasi S, Kwan L, MacGillivray J, Bansback N, De Vera MA, Barry AR, Harrison MJ, Andrade J, Lynd LD, Loewen P. Assessment of atrial fibrillation patients' education needs from patient and clinician perspectives: A qualitative descriptive study. Thromb Res 2019; 173:109-116. [DOI: 10.1016/j.thromres.2018.11.015] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2018] [Revised: 08/13/2018] [Accepted: 11/15/2018] [Indexed: 01/17/2023]
|
41
|
Barry AR, Egan G, Turgeon RD, Leung M. Evaluation of Physical Assessment Education for Practising Pharmacists: A Cross-Sectional Survey. Can J Hosp Pharm 2019; 72:27-33. [PMID: 30828091 PMCID: PMC6391243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
BACKGROUND Pharmacists are now seeking to incorporate physical assessment (PA) into their practices. This trend prompted the creation, by the British Columbia Branch of the Canadian Society of Hospital Pharmacists, of a 30-h course specifically designed for practising pharmacists. OBJECTIVE To evaluate pharmacists' knowledge, skills, and confidence in performing PA after completing the course. METHODS All course participants were invited to complete 2 anonymous online surveys, immediately and 6 months after course completion. RESULTS Of the 218 participants, 82 (38%) responded to the survey administered immediately after the course, and 77 (35%) completed this survey in full. About half of the respondents (39/79 [49%]) reported use of PA on a real patient before taking the course. Lack of formal training and lack of comfort were the most frequently selected barriers to performing PA. All respondents (79/79) agreed that the course had improved their knowledge of PA, 96% (76/79) agreed that it had improved their skills, and 90% (71/79) agreed that it had improved their ability to care for patients. In addition, 61% (48/79) and 67% (53/79), respectively, agreed that they felt confident performing PA and intervening with regard to a patient's drug therapy on the basis of physical findings. Thirty-eight (17%) of the course participants completed the 6-month follow-up survey. In that survey, the most frequently selected barrier to performing PA was lack of time. Paired data, available for 23 respondents, showed a significant increase in use of PA on real patients over time (p = 0.013 by χ2 test). However, there was no significant improvement in confidence in performing PA or intervening on a patient's drug therapy on the basis of physical findings (p > 0.05 by 2-sided t test). The primary limitation of this study was potential responder bias. CONCLUSIONS A PA course designed for pharmacists improved participants' self-reported knowledge and skills, as well as self-perceived ability to care for patients. Six months after the course, two-thirds of respondents had used PA in practice. However, there was no improvement in confidence in performing such assessments or using the findings to intervene on a patient's drug therapy.
Collapse
|
42
|
Barry AR, Mitchelmore BR. Should All Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease Receive an SGLT2 Inhibitor? Can J Hosp Pharm 2018. [DOI: 10.4212/cjhp.v71i4.2831] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
43
|
Barry AR, Chris CE. [Not Available]. CANADIAN FAMILY PHYSICIAN MEDECIN DE FAMILLE CANADIEN 2018; 64:e290-e292. [PMID: 30002037 PMCID: PMC6042677] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
|
44
|
Barry AR, Chris CE. Primary care and the RCMP: Unexpected partnership in opioid harm reduction. CANADIAN FAMILY PHYSICIAN MEDECIN DE FAMILLE CANADIEN 2018; 64:489-490. [PMID: 30002022 PMCID: PMC6042657] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
|
45
|
Abstract
Background Despite a lack of good scientific evidence for their benefit, Canadians take a lot of natural health products (NHPs). The objectives of this study were to determine patients' perception of the efficacy, safety and quality of NHPs and to characterize NHP use. Methods A standardized, 18-question survey was distributed to the general public through a variety of methods. Results A total of 326 individuals completed the survey. Eighty-five percent of respondents take 1 or more NHPs. Forty-seven percent agreed/strongly agreed that NHPs are safer than prescription medications and 24% disagreed/strongly disagreed that prescription medications are more effective than NHPs. Three-quarters of respondents agreed/strongly agreed that health care providers should recommend NHPs more often, as most stated they preferred to take an NHP for both a minor ailment (82%) and chronic medical condition (60%). Respondents used 124 different NHPs, most commonly vitamin D, vitamin B and magnesium. Respondents purchased NHPs primarily from health/vitamin stores (66%) and accessed the Internet for information about them (64%). Younger, female respondents were more likely to take NHPs. Discussion Patients appear to be comfortable foregoing education from health care professionals about the benefits and risks of NHPs. Patients' comfort with self-prescribing NHPs seems to stem from a perception of general efficacy and quality with little to no concern about harm and appears to be strongly influenced by lay sources of information. Conclusion Most respondents take 1 or more NHPs, preferring to use NHPs over prescription medications for minor and chronic health concerns seemingly based on a perception of safety and quality.
Collapse
|
46
|
Hong J, Barry AR. Long-Term Beta-Blocker Therapy after Myocardial Infarction in the Reperfusion Era: A Systematic Review. Pharmacotherapy 2018; 38:546-554. [DOI: 10.1002/phar.2110] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
47
|
Barry AR, Beach JE, Pearson GJ. Prevention and management of statin adverse effects: A practical approach for pharmacists. Can Pharm J (Ott) 2018; 151:179-188. [PMID: 29796131 DOI: 10.1177/1715163518768534] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Statin-associated adverse effects, primarily muscle-related symptoms, occur in up to approximately one-third of patients in clinical practice. Recently, a Canadian Consensus Working Group outlined 6 key principles to assess and manage patients with goal-inhibiting statin intolerance, defined as a syndrome characterized by symptoms or biomarker abnormalities that prevent the long-term use of and adherence to indicated statin therapy, which includes a trial of at least 2 statins and precludes reversible causes of statin adverse effects. These principles ensure patients are appropriately receiving a statin and aware of both the benefits and risks of therapy. As well, they address factors that may increase the risk of statin-associated myopathy. A thorough assessment of patients' clinical and laboratory history should be performed in any patient presenting with muscle symptoms on statin therapy, followed by a systematic dechallenge/rechallenge approach. In practice, most patients with statin intolerance due to muscle symptoms will be able to tolerate another statin. This is of particular importance because of the relative paucity of compelling evidence demonstrating a cardiovascular benefit with nonstatin therapies. Pharmacists are ideally situated to provide patient education, recommend changes to therapy and monitor patients with goal-inhibiting statin intolerance.
Collapse
|
48
|
|
49
|
|
50
|
Peterson SC, Barry AR. Effect of Glucagon-like Peptide-1 Receptor Agonists on All-cause Mortality and Cardiovascular Outcomes: A Meta-analysis. Curr Diabetes Rev 2018; 14:273-279. [PMID: 28413990 DOI: 10.2174/1573399813666170414101450] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/13/2017] [Revised: 03/27/2017] [Accepted: 03/29/2017] [Indexed: 11/22/2022]
Abstract
BACKGROUND Cardiovascular disease is the leading cause of death in patients with type 2 diabetes. OBJECTIVE To assess the impact of glucagon-like peptide-1 receptor agonist (GLP1RA) therapy, compared to placebo, on clinically relevant outcomes including all-cause mortality, cardiovascular mortality, nonfatal myocardial infarction (MI), nonfatal stroke, and hospitalizations for heart failure, in patients with type 2 diabetes. METHODS EMBASE, MEDLINE, and CENTRAL were searched (inception to September 2016) for randomized, double-blind, placebo-controlled trials of at least one year in duration that compared any GLP1RA to placebo in patients with type 2 diabetes. Both authors independently completed the literature search, data extraction, and risk of bias assessment. For each outcome, a Risk Ratio (RR) and 95% Confidence Interval (CI) were calculated using a Mantel-Haenszel random effects model. RESULTS Eight trials (three albiglutide, two lixisenatide, two liraglutide, one semaglutide) consisting of 21,135 patients were included. Most patients had, or were at high risk for, cardiovascular disease. Follow- up ranged from 1-3.8 years. Trials contributing the majority of data were deemed to have a low risk of bias. The risk of all-cause mortality was lowered by 11% in patients receiving a GLP1RA (RR 0.89, 95% CI 0.81-0.99). There was no statistically significant difference between groups with respect to cardiovascular death, nonfatal MI, nonfatal stroke, or hospitalizations for heart failure. CONCLUSION GLP1RA therapy when compared to placebo reduced all-cause mortality in high cardiovascular risk patients with type 2 diabetes. They did not impact cardiovascular mortality, nonfatal MI, nonfatal stroke, or heart failure hospitalizations.
Collapse
|